<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">8s4bxJgHvL4855stsNP3ckQ</article-id>
      <article-id pub-id-type="other">00015</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2006001900015</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(06)08700615</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2006001900015</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Controle microbiol&#243;gico em valvas card&#237;acas humanas</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Peruzzo</surname>
            <given-names>Angela Maria</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
          <xref ref-type="aff" rid="aff02"/>
          <xref ref-type="aff" rid="aff03"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Costa</surname>
            <given-names>Francisco Diniz Affonso da</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
          <xref ref-type="aff" rid="aff02"/>
          <xref ref-type="aff" rid="aff03"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Abrah&#227;o</surname>
            <given-names>Wanda Moscalewski</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
          <xref ref-type="aff" rid="aff02"/>
          <xref ref-type="aff" rid="aff03"/>
        </contrib>
      </contrib-group>
      <aff id="aff03">
        <addr-line>
          <named-content content-type="city">Passo Fundo</named-content>
          <named-content content-type="state">RS</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade Federal do Paran&#225;</institution>
      </aff>
      <aff id="aff01">
        <institution content-type="orgname">Cardiopr&#243;tese</institution>
      </aff>
      <aff id="aff02">
        <addr-line>
          <named-content content-type="state">Paran&#225;</named-content>
        </addr-line>
        <institution content-type="orgname">Pontif&#237;cia Universidade Cat&#243;lica do Paran&#225;</institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>12</month>
        <year>2006</year>
      </pub-date>
      <volume>87</volume>
      <issue>6</issue>
      <fpage>778</fpage>
      <lpage>782</lpage>
      <history>
        <date date-type="accepted">
          <day>28</day>
          <month>10</month>
          <year>2005</year>
        </date>
        <date date-type="received">
          <day>04</day>
          <month>08</month>
          <year>2005</year>
        </date>
        <date date-type="rev-recd">
          <day>14</day>
          <month>10</month>
          <year>2005</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>OBJETIVO: Avaliar, sob o aspecto microbiol&#243;gico, valvas processadas pelo Banco de Valvas Card&#237;acas Humanas da Irmandade da Santa Casa de Miseric&#243;rdia de Curitiba, para serem utilizadas em cirurgias cardiovasculares. M&#201;TODOS: Foi avaliado o processamento de 1.671 valvas, no per&#237;odo de junho de 1999 a junho de 2004. Das valvas e solu&#231;&#245;es envolvidas no processo foram coletadas amostras e semeadas nos meios de cultura: meio l&#237;quido tioglicolato, caldo soja tripticase&#237;na e caldo Sabouraud, com quatorze dias de incuba&#231;&#227;o, utilizando a metodologia modificada baseada na Farmacop&#233;ia Brasileira 1998 e USP 1990 (United States Pharmacopeia). Nas amostras que apresentaram crescimento foram realizadas as identifica&#231;&#245;es microbianas. RESULTADOS: Em um total de 1.671 amostras analisadas, 92% foram consideradas pr&#243;prias para utiliza&#231;&#227;o, sob o aspecto microbiol&#243;gico, uma vez que n&#227;o apresentaram contamina&#231;&#227;o microbiana. Somente 8% n&#227;o foram liberadas para uso cl&#237;nico por motivo de contamina&#231;&#227;o em alguma etapa do processamento da valva. CONCLUS&#195;O: Analisando os resultados, observou-se a import&#226;ncia do controle microbiol&#243;gico em enxertos humanos, evitando a utiliza&#231;&#227;o de valvas com contamina&#231;&#227;o microbiol&#243;gica em pacientes submetidos &#224; cirurgia cardiovascular.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Valvas card&#237;acas</kwd>
        <kwd>homoenxertos</kwd>
        <kwd>aloenxertos</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>18</day>
        <month>01</month>
        <year>2007</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>ARTIGO ORIGINAL</bold>
    </p>
    <p>
      <bold>Controle microbiol&#243;gico em valvas card&#237;acas humanas</bold>
    </p>
    <p>
      <bold>Angela Maria Peruzzo; Francisco Diniz Affonso da Costa; Wanda Moscalewski Abrah&#227;o</bold>
    </p>
    <p>Cardiopr&#243;tese - Ind. e Com. de Produtos para Sa&#250;de, Pontif&#237;cia Universidade Cat&#243;lica do Paran&#225;, Universidade Federal do Paran&#225; &#150; Passo Fundo, RS</p>
    <p>
      <xref ref-type="corresp" rid="back">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p><bold>OBJETIVO:</bold> Avaliar, sob o aspecto microbiol&#243;gico, valvas processadas pelo Banco de Valvas Card&#237;acas Humanas da Irmandade da Santa Casa de Miseric&#243;rdia de Curitiba, para serem utilizadas em cirurgias cardiovasculares. </p>
    <p><bold>M&#201;TODOS:</bold> Foi avaliado o processamento de 1.671 valvas, no per&#237;odo de junho de 1999 a junho de 2004. Das valvas e solu&#231;&#245;es envolvidas no processo foram coletadas amostras e semeadas nos meios de cultura: meio l&#237;quido tioglicolato, caldo soja tripticase&#237;na e caldo Sabouraud, com quatorze dias de incuba&#231;&#227;o, utilizando a metodologia modificada baseada na Farmacop&#233;ia Brasileira 1998 e USP 1990 (United States Pharmacopeia). Nas amostras que apresentaram crescimento foram realizadas as identifica&#231;&#245;es microbianas. </p>
    <p><bold>RESULTADOS:</bold> Em um total de 1.671 amostras analisadas, 92% foram consideradas pr&#243;prias para utiliza&#231;&#227;o, sob o aspecto microbiol&#243;gico, uma vez que n&#227;o apresentaram contamina&#231;&#227;o microbiana. Somente 8% n&#227;o foram liberadas para uso cl&#237;nico por motivo de contamina&#231;&#227;o em alguma etapa do processamento da valva. </p>
    <p><bold>CONCLUS&#195;O:</bold> Analisando os resultados, observou-se a import&#226;ncia do controle microbiol&#243;gico em enxertos humanos, evitando a utiliza&#231;&#227;o de valvas com contamina&#231;&#227;o microbiol&#243;gica em pacientes submetidos &#224; cirurgia cardiovascular.</p>
    <p><bold>Palavras-chave:</bold> Valvas card&#237;acas, homoenxertos, aloenxertos</p>
    <p>A preocupa&#231;&#227;o com a qualidade de maneira em geral tem sido uma constante para o ser humano. Quando essa qualidade est&#225; relacionada a produtos para sa&#250;de, envolve cuidados e conhecimentos ainda maiores, principalmente em se tratando de materiais invasivos como os aloenxertos.</p>
    <p>O primeiro relato da utiliza&#231;&#227;o de aloenxerto data de 1948, quando tecido humano obtido de cad&#225;ver foi implantado por Gross et al., que utilizaram segmentos arteriais<sup>1,2</sup>.</p>
    <p>A primeira implanta&#231;&#227;o de valva humana na posi&#231;&#227;o a&#243;rtica ocorreu em 24 de julho de 1962, realizada pelo Dr. Donald Ross, em Londres, no Hospital Guys<sup>3</sup>.</p>
    <p>Com a finalidade de garantir a qualidade dos tecidos processados e o controle de sua distribui&#231;&#227;o foi fundada, em 1976, a Associa&#231;&#227;o Americana dos Bancos de Tecidos<sup>4</sup>.</p>
    <p>No Brasil, a Irmandade da Santa Casa de Miseric&#243;rdia de Curitiba &#150; Hospital de Caridade disp&#245;e de um o Banco de Valvas Card&#237;acas Humanas que recebe os tecidos das Centrais de Transplantes, as quais det&#234;m o controle da capta&#231;&#227;o e utiliza&#231;&#227;o das valvas em todo o territ&#243;rio nacional. Esse Banco est&#225; cadastrado no Minist&#233;rio da Sa&#250;de de acordo as determina&#231;&#245;es da Portaria n.333/GM, de 24 de mar&#231;o de 2000<sup>5</sup>.</p>
    <p>Visando oferecer aos pacientes um substituto valvar com qualidade, o Banco de Valvas processa e estoca valvas humanas obtidas de doadores saud&#225;veis, seguindo a metodologia preconizada pelo Manual de Qualidade do Banco de Valvas Card&#237;acas Humanas da Santa Casa de Miseric&#243;rdia de Curitiba.</p>
    <p>O controle microbiol&#243;gico foi realizado em todas as etapas do processamento para quantificar e qualificar os microrganismos encontrados durante o manuseio das valvas, selecionando aquelas que se apresentam isentas de contamina&#231;&#227;o.</p>
    <p>O objetivo do trabalho foi relatar os resultados microbiol&#243;gicos encontrados na solu&#231;&#227;o transporte at&#233; a criopreserva&#231;&#227;o de cada valva, no per&#237;odo de julho de 1999 a julho de 2004.</p>
    <p>
      <bold>M&#233;todos</bold>
    </p>
    <p>O controle microbiol&#243;gico foi realizado durante o processamento de 1.671 valvas removidas de cora&#231;&#245;es de doadores sadios.</p>
    <p>Ap&#243;s a coleta (feita por equipe m&#233;dica, de acordo com procedimentos pr&#233;-estabelecidos), cada cora&#231;&#227;o foi submerso em solu&#231;&#227;o fisiol&#243;gica (solu&#231;&#227;o transporte = ST) e enviado ao Banco de Valvas Card&#237;acas Humanas da Santa Casa (BHSC) entre 2 e 8&#186;C.</p>
    <p>O processamento das valvas seguiu instru&#231;&#245;es do protocolo do Banco de Valvas Card&#237;acas Humanas da Santa Casa de Miseric&#243;rdia de Curitiba e foi realizado em fluxo laminar classe 100. Para inocula&#231;&#227;o das amostras foram preparados tr&#234;s diferentes meios de cultura (utilizando a metodologia modificada baseada na Farmacop&#233;ia Brasileira 1988 e da United States Pharmacopeia 1990<sup>6,7</sup>): meio l&#237;quido de Tioglicolato visando ao crescimento de bact&#233;rias aer&#243;bias e anaer&#243;bias; caldo Soja Tripticase&#237;na (TSB), para o crescimento de bact&#233;rias aer&#243;bias; e caldo Sabouraud, para o crescimento de fungos<sup>6-9</sup>.</p>
    <p>As amostras foram coletadas nas seguintes etapas:</p>
    <p><italic>Etapa 1</italic> &#150; Preparo da solu&#231;&#227;o para esteriliza&#231;&#227;o (SE): constitu&#237;da de 400 ml de RPMI (Gibco) e antibi&#243;ticos (cefoxitina: 240 &#181;g/ml, lincomicina: 120 &#181;g/ml, polimixina B: 100 &#181;g/ml e vancomicina: 50 &#181;g/ml). Ap&#243;s o preparo da solu&#231;&#227;o foram retirados 3 ml da solu&#231;&#227;o e foi semeado 1 ml em cada 5 ml dos diferentes meios de cultura. Depois de preparada a solu&#231;&#227;o foi deixada em geladeira at&#233; o momento o uso. RPMI: Roswell Park Memorial Institute<sup>10</sup>.</p>
    <p><italic>Etapa 2</italic> &#150; Inocula&#231;&#227;o da solu&#231;&#227;o transporte: antes da dissec&#231;&#227;o, foram retirados assepticamente 3 ml da solu&#231;&#227;o transporte e foi semeado 1 ml em cada um dos meios de cultura. Em seguida foi feita a dissec&#231;&#227;o da valva. Ap&#243;s a dissec&#231;&#227;o, foram retirados tr&#234;s fragmentos (amostras) do m&#250;sculo e da parede de cada valva, com aproximadamente 0,5 cm x 0,5 cm cada. Em seguida, cada valva e seus respectivos fragmentos foram colocados separadamente em recipientes contendo 200 ml da SE (previamente preparada na Etapa 1), permanecendo entre 2 e 8&#186;C durante 24 horas.</p>
    <p><italic>Etapa 3</italic> &#150; Transcorridas as 24 horas as valvas foram congeladas, mas, antes, foi preparada a <bold>s</bold>olu&#231;&#227;o para congelamento (SC), constitu&#237;da de 200 ml de RPMI + 25 ml de DMSO (dimetilsulf&#243;xido - MercK) e 25 ml de SFB (soro Fetal Bovino - Gibco). Foram retirados assepticamente 3 ml da SC e foi semeado 1 ml em cada um dos meios de cultura.</p>
    <p><italic>Etapa 4</italic> &#150; Inocula&#231;&#227;o das amostras s&#243;lidas (Etapa chamada de esteriliza&#231;&#227;o: E): as valvas e os fragmentos foram retirados da SE e lavados com solu&#231;&#227;o fisiol&#243;gica. Os fragmentos foram semeados nos diferentes meios de cultura (um peda&#231;o do m&#250;sculo e um peda&#231;o da parede de cada valva para cada meio utilizado).</p>
    <p><italic>Etapa 5</italic> &#150; Inocula&#231;&#227;o da etapa do congelamento (C): em seguida, cada valva foi introduzida em uma bolsa, contendo 100 ml da SC (previamente preparada na Etapa 3). Ap&#243;s cada valva entrar em contato com a solu&#231;&#227;o, antes de selar a bolsa foram retirados 3 ml da solu&#231;&#227;o e foi semeado 1 ml em cada um dos meios de cultura. Os meios de cultura foram incubados por um per&#237;odo de quatorze dias, e os meios l&#237;quidos de Tioglicolato e TSB permaneceram a uma temperatura de 35&#176;C e o caldo Sabouraud em temperatura de 22&#176;C<sup>6-9</sup>. Nas amostras positivas para os meios l&#237;quidos Tioglicolato e TSB foram realizados isolamentos em meios Mac Conkey<sup>9</sup> (Gram-negativos) e &#193;gar Sangue<sup>9</sup> de carneiro (Gram-positivos e negativos), as identifica&#231;&#245;es foram atrav&#233;s de automa&#231;&#227;o no microScan Walk Away 40 &#150; Dade Behring. Para amostras positivas em caldo Sabouraud os isolamentos foram feitos em &#193;gar Sabouraud<sup>9</sup> e as identifica&#231;&#245;es manuais, atrav&#233;s de tubos germinativos e microscopia.</p>
    <p>
      <bold>Resultados</bold>
    </p>
    <p>Em um total de 1.671 amostras analisadas, 1.535 (92%) foram consideradas adequadas e 136 (8%) inadequadas sob o aspecto microbiol&#243;gico (<xref ref-type="fig" rid="f1">fig.1</xref>).</p>
    <p content-type="asset">
      <fig id="f1">
        <graphic xlink:href="1678-4170-abc-87-06-0778-00015-gf01.jpg"/></fig>
    </p>
    <p>Foram consideradas amostras adequadas aquelas que n&#227;o apresentaram crescimento microbiano nas diferentes etapas, bem como aus&#234;ncia de crescimento ap&#243;s a etapa de esteriliza&#231;&#227;o para amostras com ST positivo.</p>
    <p>As amostras consideradas inadequadas, portanto, foram aquelas que apresentaram crescimento microbiano em uma ou mais etapas ap&#243;s a etapa de esteriliza&#231;&#227;o.</p>
    <p>Nas 1.535 amostras adequadas, 1.266 apresentaram resultado negativo em todas as etapas e 269 tiveram apenas a solu&#231;&#227;o transporte positiva, apresentando um resultado negativo ap&#243;s a esteriliza&#231;&#227;o (<xref ref-type="fig" rid="f1">fig.1</xref>).</p>
    <p>Nas 136 amostras inadequadas, as etapas com resultados positivos foram (<xref ref-type="fig" rid="f1">fig.1</xref>): solu&#231;&#227;o transporte (ST): 87; solu&#231;&#227;o para esteriliza&#231;&#227;o (SE): 4; solu&#231;&#227;o para congelamento (SC): 17; etapa da esteriliza&#231;&#227;o (E): 78; etapa do congelamento (C): 79.</p>
    <p>Os microrganismos mais freq&#252;entes encontrados em cada etapa foram:</p>
    <list list-type="bullet">
      <list-item>
        <p>Solu&#231;&#227;o para esteriliza&#231;&#227;o: </p>
        <p><italic>Rhodotorula sp</italic>. (4) (</p>
        <p><xref ref-type="fig" rid="fig15g1">gr&#225;fico 1</xref>).</p>
      </list-item>
      <list-item>
        <p>Solu&#231;&#227;o para congelamento: </p>
        <p><italic>Bacillus difter&#243;ides</italic> (3) e </p>
        <p><italic>Acinetobacter lwoffi</italic> (3) (</p>
        <p><xref ref-type="fig" rid="fig15g1">gr&#225;fico 1</xref>).</p>
      </list-item>
      <list-item>
        <p>Etapa de congelamento: </p>
        <p><italic>Staphylococcus aureus</italic> (16), Estafilococco com coagulase negativa (11), </p>
        <p><italic>Pseudomonas sp</italic> (9) e </p>
        <p><italic>Candida albicans</italic> (8) (</p>
        <p><xref ref-type="fig" rid="fig15g1">gr&#225;fico 1</xref>).</p>
      </list-item>
      <list-item>
        <p>Etapa de esteriliza&#231;&#227;o: </p>
        <p><italic>Candida albicans</italic> (11), </p>
        <p><italic>Pseudomonas sp</italic> (10), </p>
        <p><italic>Escherichia coli</italic> (8) e </p>
        <p><italic>Staphylococcus epidermidis</italic> (8) (</p>
        <p><xref ref-type="fig" rid="fig15g1">gr&#225;fico 1</xref>).</p>
      </list-item>
    </list>
    <p content-type="asset">
      <fig id="fig15g1">
        <graphic xlink:href="1678-4170-abc-87-06-0778-00015-gf02.jpg"/></fig>
    </p>
    <p>Somando as 269 amostras positivas da solu&#231;&#227;o transporte nas an&#225;lises adequadas e as 87 nas an&#225;lises inadequadas, obteve-se um total de 356 ST positivas, e os microorganismos mais freq&#252;entes foram: <italic>Staphylococcus aureus</italic> (50) <italic>Staphylococcus epidermidis</italic> (45), Estafilococo com coagulase negativa (44) (<xref ref-type="fig" rid="fig15g2">gr&#225;fico 2</xref>).</p>
    <p content-type="asset">
      <fig id="fig15g2">
        <graphic xlink:href="1678-4170-abc-87-06-0778-00015-gf03.jpg"/></fig>
    </p>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>De acordo com os resultados obtidos, pode-se considerar eficaz a metodologia utilizada no processamento das valvas, na qual 1.266 amostras foram negativas em todas as etapas (da capta&#231;&#227;o do &#243;rg&#227;o at&#233; o congelamento da valva), indicando assepsia e boas pr&#225;ticas no procedimento<sup>11</sup>.</p>
    <p>Entre as 356 amostras de ST positivas, apenas 269 foram consideradas aptas para uso cl&#237;nico sob o aspecto microbiol&#243;gico, pois apresentaram resultados negativos nas etapas subseq&#252;entes ap&#243;s a etapa de esteriliza&#231;&#227;o, mostrando a efici&#234;ncia da solu&#231;&#227;o esterilizante.</p>
    <p>A solu&#231;&#227;o transporte positiva pode indicar a contamina&#231;&#227;o do &#243;rg&#227;o propriamente dito, contamina&#231;&#227;o na sua retirada, na manipula&#231;&#227;o durante o procedimento ou na coleta da amostra. Entretanto, n&#227;o se pode afirmar onde realmente ocorreu a contamina&#231;&#227;o.</p>
    <p>Se a ST for positiva para o g&#234;nero <italic>Bacillus</italic> ou <italic>Clostridium</italic>, a valva &#233; considerada inadequada para uso, mesmo que nas demais etapas apresente resultados negativos ap&#243;s a esteriliza&#231;&#227;o, por se tratar de bact&#233;rias esporuladas dificultando a a&#231;&#227;o dos antibi&#243;ticos.</p>
    <p>Segundo o protocolo do Banco de Valvas, qualquer amostra positiva ap&#243;s a esteriliza&#231;&#227;o &#233; considerada inadequada para uso cl&#237;nico do ponto de vista microbiol&#243;gico, independentemente do microorganismo identificado, pois mostra que n&#227;o ocorreu a esteriliza&#231;&#227;o da valva.</p>
    <p>Em alguns casos &#233; esperada a presen&#231;a de bact&#233;rias e fungos ap&#243;s a Etapa de esteriliza&#231;&#227;o, em raz&#227;o da baixa concentra&#231;&#227;o de antibi&#243;ticos e da n&#227;o-utiliza&#231;&#227;o de antif&#250;ngico<sup>12</sup>, pela sua toxicidade celular.</p>
    <p>Utilizando os mesmos antibi&#243;ticos uma institui&#231;&#227;o internacional apresentou resultados semelhantes (Rebeyka IM. Policy and Procedure Manual. Hospital for Sick Children Cryopreservation Laboratory. Toronto; 1992; Ap H), mostrando a efic&#225;cia da solu&#231;&#227;o esterilizante em ambos os servi&#231;os, com a diminui&#231;&#227;o da contamina&#231;&#227;o ap&#243;s a etapa de esteriliza&#231;&#227;o e o eventual crescimento de fungos na solu&#231;&#227;o esterilizante e na etapa da esteriliza&#231;&#227;o, uma vez que n&#227;o se utilizou antif&#250;ngico em nenhum dos procedimentos, revelando assim a reprodutividade do m&#233;todo (<xref ref-type="table" rid="t1">tab.1</xref>).</p>
    <p content-type="asset">
      <table-wrap id="t1">
        <graphic xlink:href="1678-4170-abc-87-06-0778-00015-gt01.jpg"/></table-wrap>
    </p>
    <p>Finalmente, pode-se dizer que o m&#233;todo utilizado para o controle microbiol&#243;gico no processamento de valvas, at&#233; o momento, mostra-se eficaz e reprodutivo, proporcionando a pacientes submetidos a cirurgia cardiovascular um substituto isento de contamina&#231;&#227;o microbiana.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflitos de interesses pertinentes.</p>
    <p>
      <fn id="back" fn-type="corresp">
        <p>Correspond&#234;ncia:</p>
        <p>Angela Maria Peruzzo </p>
        <p> Rua Bom Pastor, 485 &#150; Sobrado 25 </p>
        <p> 81720-310 &#150; Curitiba, PR </p>
        <p> E-mail: </p>
        <p>
          <email xlink:href="angelamariaperuzzo@yahoo.com.br">angelamariaperuzzo@yahoo.com.br</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 04/08/05; revisado recebido em 14/10/05; aceito em 28/10/05.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1.  Hopkins RA. Cardiac Reconstructions with Allograft Valve. New York. Stringer Verlag; 1989: vii.</mixed-citation>
        <element-citation publication-type="book">
          <source>Cardiac Reconstructions with Allograft Valve</source>
          <date>
            <year>1989</year>
          </date>
          <fpage>vii</fpage>
          <person-group person-group-type="author">
            <name>
              <surname>Hopkins</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Nogueira A,    Lucchese FA. O papel dos homoenxertos no tratamento das cardiopatias cong&#234;nitas.    Revista Latino de la sociedade Boliviana de Cardiologia 2003;7:1-6. Dispon&#237;vel    em URL: <ext-link ext-link-type="uri" xlink:href="http://www.bago.com.bo/sbc/latido/Vol7_n1/html/cardiop_congenita.html">www.bago.com.bo/sbc/latido/Vol7_n1/html/cardiop_congenita.html</ext-link>.    Acesso em 29 de junho de 2004.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>O papel dos homoenxertos no tratamento das cardiopatias cong&#234;nitas</article-title>
          <source>Revista Latino de la sociedade Boliviana de Cardiologia</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>1</fpage>
          <lpage>6</lpage>
          <volume>7</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Nogueira</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lucchese</surname>
              <given-names>FA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Ross DN. Homograft replacent of the aortic valve. Lancet 1962; 2: 487.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Homograft replacent of the aortic valve</article-title>
          <source>Lancet</source>
          <date>
            <year>1962</year>
          </date>
          <fpage>487</fpage>
          <volume>2</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ross</surname>
              <given-names>DN</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <mixed-citation>4. American Association of Tissue Banks. Dispon&#237;vel em <ext-link ext-link-type="uri" xlink:href="http://www.aatb.org/">http://www.aatb.org/</ext-link>. Acesso em 8 de julho de 2004.</mixed-citation>
        <element-citation publication-type="other"/>
      </ref>
      <ref id="B5">
        <label>5</label>
        <mixed-citation>5. BRASIL. Minist&#233;rio da Sa&#250;de. Portaria n.333/GM de 24 de mar&#231;o 2000. Disp&#245;e sobre a regulamenta&#231;&#227;o do funcionamento e cadastramento de Bancos de Valvas Card&#237;acas Humanas.</mixed-citation>
        <element-citation publication-type="book">
          <source>Portaria n.333/GM de 24 de mar&#231;o 2000: Disp&#245;e sobre a regulamenta&#231;&#227;o do funcionamento e cadastramento de Bancos de Valvas Card&#237;acas Humanas</source>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Farmacop&#233;ia Brasileira. 4&#350; ed. S&#227;o Paulo: Ed. Atheneu; 1988: v.5.1.1-v.5.1.1.6.</mixed-citation>
        <element-citation publication-type="book">
          <source>Farmacop&#233;ia Brasileira</source>
          <date>
            <year>1988</year>
          </date>
          <fpage>v.5.1.1</fpage>
          <lpage>v.5.1.1.6</lpage>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. United States Pharmacopeial Convention. The United States Pharmacopeia. 22&#350; ed. Rockville: USP Pharmacopeia Convencion; 1990: 1684-5.</mixed-citation>
        <element-citation publication-type="book">
          <source>The United States Pharmacopeia</source>
          <date>
            <year>1990</year>
          </date>
          <fpage>1684</fpage>
          <lpage>5</lpage>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Novo OF, Auricchio MT, Bugno A, Azevedo EM, Arbex LWFV. Controle de Esterilidade de Correlatos Utilizados na Cidade de S&#227;o Paulo. Rev Inst Adolfo Lutz 1995; 55: 51-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Controle de Esterilidade de Correlatos Utilizados na Cidade de S&#227;o Paulo</article-title>
          <source>Rev Inst Adolfo Lutz</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>51</fpage>
          <lpage>5</lpage>
          <volume>55</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Novo</surname>
              <given-names>OF</given-names>
            </name>
            <name>
              <surname>Auricchio</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Bugno</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Azevedo</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Arbex</surname>
              <given-names>LWFV</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Biobr&#225;s Diagn&#243;sticos. Meios de cultura. Central Gr&#225;fica de Impress&#227;o Ltda.; 2001: 142p.</mixed-citation>
        <element-citation publication-type="book">
          <source>Meios de cultura</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>142</fpage>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Moore GE, Woods LK. Culture media for human cells. Tissue Culture Association Manual 1976; 3 (Pt1): 503-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Culture media for human cells</article-title>
          <source>Tissue Culture Association Manual</source>
          <date>
            <year>1976</year>
          </date>
          <fpage>503</fpage>
          <lpage>9</lpage>
          <volume>3</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Moore</surname>
              <given-names>GE</given-names>
            </name>
            <name>
              <surname>Woods</surname>
              <given-names>LK</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Baumgartner N, Guerrero E, Menna M, Leone F, Soratti C. Microbiologic Indicators as Quality control in a Valvular Homografts Bank. Transplantation Proceedings 2001; 33: 633-4.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Microbiologic Indicators as Quality control in a Valvular Homografts Bank</article-title>
          <source>Transplantation Proceedings</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>633</fpage>
          <lpage>4</lpage>
          <volume>33</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Baumgartner</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Guerrero</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Menna</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Leone</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Soratti</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Strickett MG,    Barratt B, MacCulloch D. Desinfection of Human Heart Valve Allografts with Antibiotics    in low concentration. Pathology 1983; 15: 457-62.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Desinfection of Human Heart Valve Allografts with Antibiotics in low concentration</article-title>
          <source>Pathology</source>
          <date>
            <year>1983</year>
          </date>
          <fpage>457</fpage>
          <lpage>62</lpage>
          <volume>15</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Strickett</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Barratt</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>MacCulloch</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Microbiologyc control in human heart valves</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>OBJECTIVE: To evaluate, from microbiological point of view, the valves processed by Human Heart Valve Bank of Santa Casa de Miseric&#243;rdia of Curitiba for use in cardiovascular surgeries. METHODS: The processing of 1,671 valves, accomplished within the period of time between July 1999 and June 2004, was evaluated. Out of the valves and the solutions involved in the process, samples were collected and spread in culture mediums, such as fluid thioglycollate medium, tryptic soy broth and Sabouraud broth, for incubation during 14 days, using a modified methodology based on the Farmacop&#233;ia Brasileira 1988 (Brazilian Pharmacopeia) and USP 1990 (United States Pharmacopeia). The samples in which growing was observed were submitted to microbian identification. RESULTS: In a set of 1,671 samples, 92% were considered proper for use under microbiological point of view, since they did not display microbian contamination. The remaining 8% were rejected for clinical use because of contamination in some stage of the valve processing. CONCLUSION: From the Analysis of the results, it was observed the importance of microbiological control in human grafts, in order to avoid using microbiologically contaminated valves in patients submitted to cardiovascular surgery.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Cardiac valves</kwd>
        <kwd>homografts</kwd>
        <kwd>allografts</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ORIGINAL ARTICLE</bold>
      </p>
      <p>
        <bold>Microbiologyc control in human heart valves</bold>
      </p>
      <p>
        <bold>Angela Maria Peruzzo; Francisco Diniz Affonso da Costa; Wanda Moscalewski Abrah&#227;o</bold>
      </p>
      <p>Cardiopr&#243;tese - Ind. e Com. de Produtos para Sa&#250;de, Pontif&#237;cia Universidade Cat&#243;lica do Paran&#225;, Universidade Federal do Paran&#225;, Passo Fundo, RS, Brazil</p>
      <p>
        <xref ref-type="corresp" rid="back-body2">Mailing Address</xref>
      </p>
      <p>
        <bold>ABSTRACT</bold>
      </p>
      <p><bold>OBJECTIVE:</bold> To evaluate, from a microbiological point of view, the valves processed by the Human Heart Valve Bank of Santa Casa de Miseric&#243;rdia of Curitiba for use in cardiovascular surgeries.</p>
      <p><bold>METHODS:</bold> The processing of 1,671 valves in the period from June 1999 through June 2004 was evaluated. Samples were collected from the valves and the solutions involved in the process and spread on culture media such as fluid thioglycolate medium, trypticasein soy broth and Sabouraud broth for incubation during 14 days, using a modified methodology based on Farmacop&#233;ia Brasileira 1998 (Brazilian Pharmacopeia) and USP 1990 (United States Pharmacopeia). The samples in which growing was observed were submitted to microbial identification.</p>
      <p><bold>RESULTS:</bold> Of a total of 1,671 samples, 92% were considered adequate for use from a microbiological point of view, as they did not show microbial contamination. Only 8% were not released for clinical use because of contamination at some stage of the valve processing.</p>
      <p><bold>CONCLUSION:</bold> On analyzing the results, we noticed the importance of microbiological control in human grafts to avoid using microbiologically contaminated valves in patients undergoing cardiovascular surgery.</p>
      <p><bold>Key words:</bold> Heart valves, homografts, allografts.</p>
      <p>Human beings have always been very concerned about quality. When quality is related with health products, it entails even greater care and knowledge, especially as regards invasive materials such as allografts.</p>
      <p>The use of allografts was first reported in 1948, when human tissue obtained from a corpse was implanted by Gross et al. who used arterial segments<sup>1,2</sup>.</p>
      <p>The first implantation of a human valve in the aortic position took place in July 24 1962 and was carried out by Dr. Donald Ross at Guy's Hospital<sup>3</sup> in London.</p>
      <p>The American Association of Tissue Banks<sup>4</sup> was founded in 1976 to ensure the quality of the tissues processed and control their distribution.</p>
      <p>In Brazil, Irmandade da Santa Casa de Miseric&#243;rdia of Curitiba &#150; Charity Hospital has a Human Heart Valve Bank that receives tissues from the Transplant Centrals which control the recovery and use of valves within Brazil. This bank is registered at the Ministry of Health in compliance with the provisions of Ordinance n.333/GM of March 24 2000<sup>5</sup>.</p>
      <p>In order to provide patients with quality valve replacements, the Valve Bank processes and stores human valves recovered from healthy donors following the methodology recommended by the Quality Manual of the Human Heart Valve Bank of Santa Casa de Miseric&#243;rdia of Curitiba.</p>
      <p>The microbiological control was carried out at all the stages of the processing to quantify and qualify the microorganisms found during the handling of the valves, selecting those valves which were found to be free of contamination.</p>
      <p>The objective of this paper was to report the microbiological results for the transportation solution until the cryopreservation of each valve in the period from July 1999 through July 2004.</p>
      <p>
        <bold>Methods</bold>
      </p>
      <p>The microbiological control was carried out during the processing of 1,671 valves removed from the hearts of healthy donors.</p>
      <p>After the recovery(carried out by a medical team according to pre-established procedures), each heart was immersed in saline solution (transportation solution = TS) and sent to the Human Heart Valve Bank of Santa Casa (BHSC) at a temperature between 2 and 8&#186;C.</p>
      <p>The processing of the valves followed the instructions of the protocol of the Human Heart Valve Bank of Santa Casa de Miseric&#243;rdia of Curitiba and was carried out in a class 100 laminar flow. For the inoculation of the samples, we prepared three different culture media (using a modified methodology based on the Brazilian Pharmacopeia 1988 and on the United States Pharmacopeia 1990<sup>6,7</sup>): fluid thioglycolate medium for growing aerobic and anaerobic bacteria, trypticasein soy broth (TSB) for the growing of aerobic bacteria and Sabouraud broth for the growing of fungi<sup>6-9</sup>.</p>
      <p>The samples were collected at the following stages:</p>
      <p><italic>Stage 1</italic> &#150; Preparation of the sterilizing solution (SS): with 400 ml of RPMI (Gibco) and antibiotics (cefoxitin: 240 &#181;g/ml, lincomycin: 120 &#181;g/ml, polymyxin B: 100 &#181;g/ml and vancomycin: 50 &#181;g/ml). After the preparation of the solution, 3 ml were taken, and 1 ml was spread on each of the 5 ml of each media. Once the solution was ready, it was stored in the refrigerator until the time of use. RPMI: Roswell Park Memorial Institute<sup>10</sup>.</p>
      <p><italic>Stage 2</italic> &#150; Inoculation of the transportation solution: before the dissection, 3 ml of the solution were aseptically taken from the transportation solution and 1 ml was spread on each of the culture media. Then the valve was dissected. After the dissection, three fragments (samples) of the muscle and wall of each valve with approximately 0.5 cm x 0.5 cm each were removed. Then each valve and its respective fragments were placed separately in containers with 200 ml of the SS (prepared in Stage 1), at between 2&#186; and 8&#186;C during 24 hours.</p>
      <p><italic>Stage 3</italic> &#150; After 24 hours, the valves were frozen in a freezing solution (FS) made up of 200 ml of RPMI + 25 ml of DMSO (dimethyl sulfoxide - Merck) and 25 ml of FBS (fetal bovine serum - Gibco) previously prepared. Three milliliters were aseptically taken from the FS and 1 ml was spread in each of the culture media.</p>
      <p><italic>Stage 4</italic> &#150; Inoculation of solid samples (called the Sterilization Stage: S): the valves and fragments were taken from the SS and washed with saline solution. The fragments were spread in the different culture media (a piece of muscle and a piece of the wall of each valve were spread on each medium used).</p>
      <p><italic>Stage 5</italic> &#150; Inoculation at the freezing stage (F): each valve was then introduced into a bag with 100 ml of FS (previously prepared at Stage 3). After each valve had been in contact with the solution and before the bag was sealed, 3 ml of the solution were taken, and 1 ml was spread on each one of the culture media. The culture media were incubated for fourteen days. The tioglycolate fluid and the TSB media were kept at a temperature of 35&#176;C and the Sabouraud broth was kept at a temperature of 22&#176;C<sup>6-9</sup>. In the positive samples of tioglycolate and TSB fluid media, we carried out isolations in Mac Conkey<sup>9</sup> (Gram negative) and sheep blood agar<sup>9</sup> (Gram positive and negative) media; identification was carried out in an automated fashion using a Dade Behring MicroScan WalkAway 40. For positive samples of Sabouraud broth, isolation was carried out in Agar Sabouraud<sup>9</sup> and identification was performed manually using germinative tubes and microscopic examination.</p>
      <p>
        <bold>Results</bold>
      </p>
      <p>Of a total of 1,671 samples analyzed, 1,535 (92%) were considered adequate and 136 (8%) were considered inadequate from a microbiological point of view (<xref ref-type="fig" rid="e15f1-body2">Fig.1</xref>).</p>
      <p content-type="asset">
        <fig id="e15f1-body2">
          <graphic xlink:href="1678-4170-abc-87-06-0778-00015-gf01-en.jpg"/></fig>
      </p>
      <p>Adequate samples were those which did not present microbial growth at the different stages, with absence of growth after the sterilization stage for those samples with positive TS.</p>
      <p>The samples considered inadequate therefore were those which presented microbial growth in one or more stages after the sterilization stage.</p>
      <p>Of the 1,535 adequate samples, 1,266 had negative results at all the stages and in 269 only the transportation solution was positive, with negative results after the sterilization process (<xref ref-type="fig" rid="e15f1-body2">Fig.1</xref>).</p>
      <p>For the 136 inadequate samples, the stages with positive results were (<xref ref-type="fig" rid="e15f1-body2">fig.1</xref>): transportation solution (TS): 87; sterilizing solution (SS): 4; freezing solution (FS): 17; sterilizing stage (S): 78; freezing stage (F): 79.</p>
      <p>The most frequently found microorganisms at each stage were:</p>
      <list list-type="bullet">
        <list-item>
          <p>Sterilizing solution: </p>
          <p><italic>Rhodotorula sp</italic>. (4) (</p>
          <p><xref ref-type="fig" rid="e15g1-body2">graph 1</xref>).</p>
        </list-item>
        <list-item>
          <p>Freezing solution: </p>
          <p><italic>Bacillus diphtheroids</italic> (3) and </p>
          <p><italic>Acinetobacter lwoffi</italic> (3) (</p>
          <p><xref ref-type="fig" rid="e15g1-body2">graph 1</xref>).</p>
        </list-item>
        <list-item>
          <p>Freezing stage: </p>
          <p><italic>Staphylococcus aureus</italic> (16), coagulase-negative staphylococcus (11), </p>
          <p><italic>Pseudomonas sp</italic> (9) and </p>
          <p><italic>Candida albicans</italic> (8) (</p>
          <p><xref ref-type="fig" rid="e15g1-body2">graph 1</xref>).</p>
        </list-item>
        <list-item>
          <p>Sterilizing stage: </p>
          <p><italic>Candida albicans</italic> (11), </p>
          <p><italic>Pseudomonas sp</italic> (10), </p>
          <p><italic>Escherichia coli</italic> (8) and </p>
          <p><italic>Staphylococcus epidermidis</italic> (8) (</p>
          <p><xref ref-type="fig" rid="e15g1-body2">graph 1</xref>).</p>
        </list-item>
      </list>
      <p content-type="asset">
        <fig id="e15g1-body2">
          <graphic xlink:href="1678-4170-abc-87-06-0778-00015-gf02-en.jpg"/></fig>
      </p>
      <p>By adding the 269 positive samples of the transportation solution of the adequate analyses and the 87 of the inadequate analyses we obtained a total of 356 TS that tested positive in that the most frequent microorganisms were: <italic>Staphylococcus aureus</italic> (50) <italic>Staphylococcus epidermidis</italic> (45) and coagulase-negative staphylococcus (44) (<xref ref-type="fig" rid="e15g2-body2">graph 2</xref>).</p>
      <p content-type="asset">
        <fig id="e15g2-body2">
          <graphic xlink:href="1678-4170-abc-87-06-0778-00015-gf03-en.jpg"/></fig>
      </p>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>According to the results obtained, we can consider that the methodology used in the processing of the valves is correct, since 1,266 samples were negative at all the stages (from the recovery of the organ through the freezing of the valve), indicating asepsis and good practices throughout the procedure<sup>11</sup>.</p>
      <p>From the 356 positive TS samples, only 269 were considered suitable for clinical use from a microbiological point of view, since they presented negative results at the stages following the sterilization stage, which shows the efficiency of the sterilizing solution.</p>
      <p>The positive transportation solution may indicate the contamination of the organ itself, contamination during its removal, during handling throughout the procedure or during the collection of the sample. However, it is not possible to say exactly where the contamination took place.</p>
      <p>If the TS tests positive for the <italic>Bacillus</italic> or <italic>Clostridium</italic> genus, the valve is considered inadequate for use, even though at the other stages it comes to present negative results after sterilization, because these bacteria are sporulated, which makes antibiotic action more difficult.</p>
      <p>According to the protocol of the Valve Bank, any positive samples after sterilization are considered inadequate for clinical use from a microbiological point of view, regardless of the microorganism identified, because it shows that the valve has not been sterilized.</p>
      <p>In some cases, the presence of bacteria and fungi is expected after the sterilization stage, due to the low concentration of antibiotics and to the non-use of antifungal agents<sup>12</sup> because of their toxicity to cells.</p>
      <p>An international institution presented similar results using the same antibiotics (Rebeyka IM. Policy and Procedure Manual. Hospital for Sick Children Cryopreservation Laboratory. Toronto; 1992; Ap H) which shows the efficacy of the sterilizing solution in both clinics, with the reduction of contamination after the sterilization stage and the occasional growth of fungi in the sterilizing solution and at the sterilization stage, since no antifungal agent was used in any of the procedures, thus showing the reproducibility of the method (<xref ref-type="table" rid="e15t1-body2">Tab. 1</xref>).</p>
      <p content-type="asset">
        <table-wrap id="e15t1-body2">
          <graphic xlink:href="1678-4170-abc-87-06-0778-00015-gt01-en.jpg"/></table-wrap>
      </p>
      <p>Finally we can say that the method used for microbiological control in the processing of valves has so far shown to be effective and reproducible, providing patients undergoing cardiovascular surgery with a replacement free of microbial contamination.</p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>References</bold>
      </p>
      <p>
        <fn id="back-body2" fn-type="corresp">
          <label>
            <bold>Mailing Address:</bold>
          </label>
          <p> Angela Maria Peruzzo</p>
          <p> Rua Bom Pastor, 485 &#150; Sobrado 25</p>
          <p> 81720-310 &#150; Curitiba, PR, Brazil</p>
          <p> E-mail: </p>
          <p>
            <email xlink:href="angelamariaperuzzo@yahoo.com.br">angelamariaperuzzo@yahoo.com.br</email>
          </p>
        </fn>
      </p>
      <p>Manuscript received August 4, 2005; revised manuscript received October 14, 2005; accepted October 28, 2005.</p>
    </body>
  </sub-article>
</article>
